Log In
Print this Print this

CTL019 (formerly CART-19)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionAutologous T cells loaded with a lentiviral vector expressing CART-19, which consists of a cancer antigen-binding domain targeting CD19 linked to CD3zeta/CD137 immunostimulatory domains
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Lentivirus

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today